Home›Companies›Biotech & Pharma›Switchpoint Bio

SwitchPoint Bio Holding, Inc.

Analyzes blood cell biology for drug developers and clinical researchers.

Updated Nov 11, 2026·Latest SEC filing Mar 10, 2026·Suggest an edit

About Switchpoint Bio

Switchpoint Bio is a private company based in Wilmington, Delaware, incorporated in 2025 in Delaware. It has reported $5,270,000 raised in one offering on Form D since March 2026. Its chief executive is Samuel Myllykangas.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 9, 2026Mar 10, 2026$5,270,000fully sold6$878KEquityRule 506(c)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Switchpoint Bio's Form D filed Mar 10, 2026.

JP
Jussi Paananen
CTO & Co-founder, director
DP
SM
Samuel Myllykangas
CEO & Co-founder, director

Sources

  1. SECSwitchPoint Bio Holding, Inc. filing history
  2. CompanyAbout Switchpoint Bio